3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Unknown
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
12
Gastrointestinal
5
Genitourinary
4
Breast
3
Tumor-Agnostic
2
Other solid neoplasm
2
Head & Neck
2
CNS
2
Thoracic
1
Sarcoma
1
Dermatologic
1
Classical hematology
1
Conditions
Head and Neck Neoplasms
2
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Cisplatin
57
pembrolizumab
54
Cetuximab
43
Radiotherapy
35
Docetaxel
21
Radiotherapy, Intensity-Modulated
20
Paclitaxel
19
Nivolumab
18
Fluorouracil
18
Carboplatin
17
Radiation
14
Radiosurgery
9
Magnetic Resonance Spectroscopy
8
Gemcitabine
8
Everolimus
8
Biopsy
8
Surgical Procedures, Operative
7
Oxaliplatin
7
Cyclophosphamide
7
durvalumab
6
avelumab
6
Erlotinib Hydrochloride
6
Capecitabine
6
spartalizumab
5
epacadostat
5
Surveys and Questionnaires
5
Platinum
5
Immunoglobulin G
5
Gefitinib
5
Dexamethasone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
niraparib
×
Head & Neck
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts